Spruce Biosciences (SPRB)

Executive Summary

Spruce Biosciences is a public biotechnology company focused on developing therapies for underserved neurological conditions, with its lead investigational therapy TA-ERT targeting MPS IIIB (Sanfilippo Syndrome Type B). The company has faced significant setbacks, as its earlier pipeline candidates for congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS) were terminated in Phase 2 due to strategic reprioritization or efficacy concerns. Despite these challenges, Spruce continues to advance TA-ERT, which is currently in Phase 3 development for MPS IIIB, a rare and devastating lysosomal storage disorder with no approved treatments. The company's commitment to this indication is supported by scientific rationale and patient advocacy, but the lack of public clinical data for TA-ERT and the prior terminated trials raise questions about execution and pipeline depth. Financially, Spruce has a modest market valuation of ~$155 million and a low share count, indicating limited capital runway, which may necessitate additional funding or partnerships to complete development and potential commercialization.

Upcoming Catalysts (preview)

• H2 2026Phase 3 TA-ERT interim data readout40% success
• 2026Regulatory alignment or fast track designation for TA-ERT50% success
• H1 2027Partnership or licensing deal to strengthen balance sheet30% success